Dyskinesia – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Dyskinesia – Pipeline Review, H2 2019’, provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Dyskinesia

– The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects

– The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Dyskinesia”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dyskinesia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Addex Therapeutics Ltd

Amarantus Bioscience Holdings Inc

Astraea Therapeutics LLC

Cadent Therapeutics Inc

Cannabis Science Inc

Cavion LLC

Cerevance Inc

Clevexel Pharma SAS

Contera Pharma ApS

DanPET AB

EpiVax Inc

GW Pharmaceuticals Plc

H. Lundbeck AS

Hua Medicine Shanghai Ltd

Ipsen SA

IRLAB Therapeutics AB

Junaxo Inc

Med-Life Discoveries LP

Medytox Inc

Melior Pharmaceuticals II LLC

Merz Pharma GmbH & Co KgaA

MitoDys Therapeutics Ltd

Motac Neuroscience Ltd

NeurAxon Pharma Inc

Neurim Pharmaceuticals Ltd

Neurocea Pharmaceuticals

Neurocrine Biosciences Inc

Neurolixis Inc

Newron Pharmaceuticals SpA

Nissan Chemical Corp

OB Pharmaceuticals

Peptron Inc

PolyCore Therapeutics LLC

Praxis Precision Medicines Australia Pty Ltd

Prilenia Therapeutics Development Ltd

Revance Therapeutics Inc

Sage Therapeutics Inc

SalubRx Therapeutics Inc

Sinopia Biosciences Inc

SOM Biotech SL

Sosei Heptares

Trevi Therapeutics Inc

Ultragenyx Pharmaceutical Inc

VistaGen Therapeutics Inc”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Dyskinesia Overview 6

Dyskinesia Therapeutics Development 7

Dyskinesia Therapeutics Assessment 16

Dyskinesia Companies Involved in Therapeutics Development 24

Dyskinesia Drug Profiles 36

Dyskinesia Dormant Projects 159

Dyskinesia Discontinued Products 162

Dyskinesia Product Development Milestones 163

Appendix 175

List of Tables

“List of Tables

Table 1: Number of Products under Development for Dyskinesia, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Universities/Institutes, H2 2019

Table 5: Products under Development by Companies, H2 2019

Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 8: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 9: Products under Development by Universities/Institutes, H2 2019

Table 10: Number of Products by Stage and Target, H2 2019

Table 11: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 12: Number of Products by Stage and Mechanism of Action, H2 2019

Table 13: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 14: Number of Products by Stage and Route of Administration, H2 2019

Table 15: Number of Products by Stage and Molecule Type, H2 2019

Table 16: Dyskinesia – Pipeline by Addex Therapeutics Ltd, H2 2019

Table 17: Dyskinesia – Pipeline by Amarantus Bioscience Holdings Inc, H2 2019

Table 18: Dyskinesia – Pipeline by Astraea Therapeutics LLC, H2 2019

Table 19: Dyskinesia – Pipeline by Cadent Therapeutics Inc, H2 2019

Table 20: Dyskinesia – Pipeline by Cannabis Science Inc, H2 2019

Table 21: Dyskinesia – Pipeline by Cavion LLC, H2 2019

Table 22: Dyskinesia – Pipeline by Cerevance Inc, H2 2019

Table 23: Dyskinesia – Pipeline by Clevexel Pharma SAS, H2 2019

Table 24: Dyskinesia – Pipeline by Contera Pharma ApS, H2 2019

Table 25: Dyskinesia – Pipeline by DanPET AB, H2 2019

Table 26: Dyskinesia – Pipeline by EpiVax Inc, H2 2019

Table 27: Dyskinesia – Pipeline by GW Pharmaceuticals Plc, H2 2019

Table 28: Dyskinesia – Pipeline by H. Lundbeck AS, H2 2019

Table 29: Dyskinesia – Pipeline by Hua Medicine Shanghai Ltd, H2 2019

Table 30: Dyskinesia – Pipeline by Ipsen SA, H2 2019

Table 31: Dyskinesia – Pipeline by IRLAB Therapeutics AB, H2 2019

Table 32: Dyskinesia – Pipeline by Junaxo Inc, H2 2019

Table 33: Dyskinesia – Pipeline by Med-Life Discoveries LP, H2 2019

Table 34: Dyskinesia – Pipeline by Medytox Inc, H2 2019

Table 35: Dyskinesia – Pipeline by Melior Pharmaceuticals II LLC, H2 2019

Table 36: Dyskinesia – Pipeline by Merz Pharma GmbH & Co KgaA, H2 2019

Table 37: Dyskinesia – Pipeline by MitoDys Therapeutics Ltd, H2 2019

Table 38: Dyskinesia – Pipeline by Motac Neuroscience Ltd, H2 2019

Table 39: Dyskinesia – Pipeline by NeurAxon Pharma Inc, H2 2019

Table 40: Dyskinesia – Pipeline by Neurim Pharmaceuticals Ltd, H2 2019

Table 41: Dyskinesia – Pipeline by Neurocea Pharmaceuticals, H2 2019

Table 42: Dyskinesia – Pipeline by Neurocrine Biosciences Inc, H2 2019

Table 43: Dyskinesia – Pipeline by Neurolixis Inc, H2 2019

Table 44: Dyskinesia – Pipeline by Newron Pharmaceuticals SpA, H2 2019

Table 45: Dyskinesia – Pipeline by Nissan Chemical Corp, H2 2019

Table 46: Dyskinesia – Pipeline by OB Pharmaceuticals, H2 2019

Table 47: Dyskinesia – Pipeline by Peptron Inc, H2 2019

Table 48: Dyskinesia – Pipeline by PolyCore Therapeutics LLC, H2 2019

Table 49: Dyskinesia – Pipeline by Praxis Precision Medicines Australia Pty Ltd, H2 2019

Table 50: Dyskinesia – Pipeline by Prilenia Therapeutics Development Ltd, H2 2019

Table 51: Dyskinesia – Pipeline by Revance Therapeutics Inc, H2 2019

Table 52: Dyskinesia – Pipeline by Sage Therapeutics Inc, H2 2019

Table 53: Dyskinesia – Pipeline by SalubRx Therapeutics Inc, H2 2019

Table 54: Dyskinesia – Pipeline by Sinopia Biosciences Inc, H2 2019

Table 55: Dyskinesia – Pipeline by SOM Biotech SL, H2 2019

Table 56: Dyskinesia – Pipeline by Sosei Heptares, H2 2019

Table 57: Dyskinesia – Pipeline by Trevi Therapeutics Inc, H2 2019

Table 58: Dyskinesia – Pipeline by Ultragenyx Pharmaceutical Inc, H2 2019

Table 59: Dyskinesia – Pipeline by VistaGen Therapeutics Inc, H2 2019

Table 60: Dyskinesia – Dormant Projects, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Dyskinesia, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019

Figure 8: Number of Products by Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports